Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

MSF disputes Tufts’ estimates on cost of drug development

Center for the Study of Drug Development says it takes up to $2.5bn to bring a drug to market

- PMLiVE

NICE wants more info on Novartis’ Xolair in chronic hives

Says company must provide more data on the drug's effectiveness

- PMLiVE

PCSK9 inhibitor alirocumab works in statin-intolerance

Sanofi and Regeneron’s drug impresses at American Heart Association meeting

Jacques Dumas joins Nosopharm scientific advisory board

French biotech's appointments also include Dominique Breilh

- PMLiVE

Charity coalition pledges millions for brain disease research

Will invest £30m developing candidates for neurodegenerative conditions

- PMLiVE

The impact of the US Sunshine Act

A new dawn begins for pharma’s payments to doctors in the US

- PMLiVE

Reckitt to spin-off pharma unit as Indivior

Demerged business will focus on opioid dependence product Suboxone

- PMLiVE

AZ says cancer will be ‘sixth growth platform’

Firm currently has 14 drugs in phase III trials

- PMLiVE

Merck’s ezetimibe has ‘modest’ benefit when added to statins

Combination showed a reduction in cardiovascular events in patients with ACS

- PMLiVE

Creston Health rebrands under Health Unlimited banner

Agencies including Red Door and PAN will operate separately and together

- PMLiVE

Actavis looks to PepsiCo for CFO

Maria Teresa Hilado will help guide company through Allergan aquisition

- PMLiVE

Actavis to buy Allergan for $66bn

Ends Valeant’s pursuit of Botox maker

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links